CN112121105B - Mouthwash spray for pets and preparation method thereof - Google Patents
Mouthwash spray for pets and preparation method thereof Download PDFInfo
- Publication number
- CN112121105B CN112121105B CN202010965262.7A CN202010965262A CN112121105B CN 112121105 B CN112121105 B CN 112121105B CN 202010965262 A CN202010965262 A CN 202010965262A CN 112121105 B CN112121105 B CN 112121105B
- Authority
- CN
- China
- Prior art keywords
- medicine components
- mouthwash
- pets
- traditional chinese
- spray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The invention relates to a mouthwash spray for pets and a preparation method thereof. The mouthwash spray for pets comprises the following raw material components: traditional Chinese medicine components, western medicine components and pH buffer solution; the traditional Chinese medicine composition comprises, by weight, 2.2-27% of traditional Chinese medicine components, which include: 0.1-1% of tea polyphenol, 1-15% of chlorogenic acid, 0.1-1% of menthol and 1-10% of xylitol; the western medicine components account for 1.3-14.5%, and include: 1-10% of ornidazole, 0.1-2% of lincomycin, 0.1-0.5% of mometasone furoate, and vitamin B20.1-2%; the pH buffer solution accounts for 58.5-95.5%. The mouthwash spray for pets contains the traditional Chinese medicine components, the western medicine components and the buffer solution, can fully exert the synergistic effect between the traditional Chinese medicine components and the western medicine components, and has high effective medicine utilization degree, good effect and difficult generation of drug resistance when being used for preventing and treating oral diseases.
Description
Technical Field
The invention relates to the technical field of veterinary drug preparation, and particularly relates to a mouthwash spray for pets and a preparation method thereof.
Background
In recent years, the number of family pets has increased dramatically, and some pets have become one of family members. However, due to various pathogenic factors and/or diet, oral diseases such as oral ulcer, gingivitis, periodontitis, glossitis, dental calculus, halitosis and the like of pets are caused, and the pet food consumption is reduced, the pets are thin, the pets are not chewed completely, digestive system diseases, the immunity is reduced and the like.
At present, clinical treatment and prevention measures for oral diseases are limited, and the oral liquid mainly comprises tooth cleaning, oral antiviral drugs and oral antibacterial drugs, and achieves certain effects. However, oral diseases belong to local diseases, and the oral medicine for systemic treatment has low utilization rate and large dosage; meanwhile, after the oral antiviral and/or antibacterial drugs are used for treating the infection to eliminate, inflammatory symptoms often exist, which shows that oral inflammation is more difficult to treat than the infection per se; in addition, due to viral variation, increased bacterial and fungal resistance, high recurrence rates, chronic infections develop.
Therefore, starting from the aspect of traditional Chinese medicine, the development of the pet mouthwash spray for preventing and treating oral diseases of pets is of great significance.
Disclosure of Invention
In view of the above, there is a need for a mouthwash spray for pets and a preparation method thereof, which are used to solve the technical problems of low availability, poor effect and easy generation of drug resistance of effective drugs in the existing methods for preventing and treating oral diseases in the prior art.
The invention provides a pet mouthwash spray, which comprises the following raw material components: traditional Chinese medicine components, western medicine components and pH buffer solution; according to the weight percentage, the weight percentage of the alloy is,
the traditional Chinese medicine composition accounts for 2.2-27%, and comprises the following components: 0.1-1% of tea polyphenol, 1-15% of chlorogenic acid, 0.1-1% of menthol and 1-10% of xylitol;
the western medicine components account for 1.3-14.5%, and include: 1-10% of ornidazole and linke0.1-2% of mycin, 0.1-0.5% of mometasone furoate and vitamin B2 0.1～2％；
The pH buffer solution accounts for 58.5-95.5%.
Further, the traditional Chinese medicine components account for 6-27%, the western medicine components account for 1.5-14%, and the pH buffer solution accounts for 61-87%.
Further, the mass ratio of the traditional Chinese medicine components to the western medicine components is (0.4-4.5): 1.
further, the mass ratio of chlorogenic acid to menthol is 1: (0.01-0.3).
Further, the pH value of the mouthwash spray for pets is controlled to be 6.5-7.5.
Further, the pH buffer is a phosphate buffer and/or a carbonate buffer.
Furthermore, in the phosphate buffer solution, the mass fraction of the disodium hydrogen phosphate is 0.454-1.945 wt%, and the mass fraction of the sodium dihydrogen phosphate is 0.756-2.016 wt%.
The second aspect of the invention provides a preparation method of a mouthwash spray for pets, which comprises the following steps: the raw materials are proportioned according to the proportion and evenly mixed to obtain the solution type spray of the mouthwash for pets.
The main raw materials of the invention have the following pharmacodynamic functions:
tea polyphenol is a general term of polyphenol substances in tea leaves, and comprises the following main components: flavanones, anthocyanidins, flavonols, anthocyanins, phenolic acids and dephenolic acids 6 compounds, and tea polyphenols have multiple physiological activities of resisting oxidation, preventing radiation, resisting aging, reducing blood fat, reducing blood sugar, inhibiting bacteria and inhibiting enzymes and the like; in the aspect of medicine, tea polyphenol has the following effects: lowering blood pressure, resisting blood coagulation, reducing blood lipid, preventing and treating cardiovascular diseases such as arteriosclerosis and thrombosis, lowering blood sugar, preventing and treating diabetes, and killing bacteria and viruses; preventing and treating diseases of gastrointestinal tract, respiratory tract, influenza, etc.; preventing and treating hepatitis, resisting aging and enhancing immunity; has effects in strengthening teeth, preventing and treating periodontitis, preventing dental caries, and removing odor and toxic materials. In addition, the tea polyphenols can prevent the damage of sunlight to skin.
Chlorogenic acid is one of the main antibacterial and antiviral effective pharmacological components of flos Lonicerae, has wide bioactivity, and has antibacterial, antiviral, leukocyte increasing, liver protecting, gallbladder function promoting, antitumor, blood pressure lowering, blood lipid reducing, free radical scavenging, and central nervous system exciting effects.
Menthol is the main component of peppermint and peppermint essential oil, and can be used as irritant in medicine, and has effects of refreshing and relieving itching; it can be used as wind-expelling medicine for treating headache, and inflammation of nose, pharynx, and larynx.
Xylitol is a natural sweetener extracted from plant materials such as birch, oak, corn cob, bagasse, etc., and has effects of protecting teeth, stabilizing blood sugar, improving liver function, resisting ketone body function, preventing tympanitis, preventing senile constipation, and regulating intestinal tract function.
Ornidazole is used for treating anaerobic bacteria, protozoa, trichomonad, etc., such as bacteroides fragilis, bacteroides dieldii, bacteroides ovatus, bacteroides thetaiotaomicron, bacteroides vulgatus, clostridium, eubacterium, peptococcus and peptococcus, helicobacter pylori, bacteroides melanoides, clostridium, CO2Infectious diseases caused by sensitive anaerobes such as bacteriophage phagemid and gingival bacillus; ornidazole interacts with cellular components through the nitro group in the molecule, either by reduction to an amino group in an anaerobic environment or by the formation of free radicals, leading to the death of the microorganism.
Lincomycin belongs to lincomycin antibiotics, is a 50S subunit acting on sensitive bacterial ribosome, can prevent the extension of a peptide chain, thereby inhibiting the protein synthesis of bacterial cells, and is commonly used for respiratory tract infection, skin soft tissue infection, female genital tract and pelvic cavity infection caused by staphylococcus, streptococcus pyogenes, pneumococcus and anaerobic bacteria, abdominal cavity infection caused by anaerobic bacteria and the like.
Mometasone furoate is a new external-use non-fluorinated type, but contains a halogen 'potent' glucocorticoid steroid hormone preparation, the dosage of which exerts local anti-inflammatory action can not cause systemic action, and the preparation has the characteristics of increased action strength and disproportionate increase of adverse reaction; after being absorbed by oral mucosa, the mometasone furoate is combined with glucocorticoid receptor protein in cytoplasm to play stronger roles of resisting inflammation, resisting allergy, contracting blood vessels, reducing vascular permeability, reducing exudation, inhibiting cell division and the like. And can enhance Th1 (helper T cell 1) reaction, inhibit Th2 (helper T cell 2) reaction, and balance the original Th1/Th2 imbalance. Adverse reactions such as oral mucosa atrophy or adrenal cortex function inhibition are not easy to cause; is suitable for treating oral diseases effectively treated by corticosteroid.
Vitamin B2Riboflavin, also called as riboflavin, is a component of the prosthetic group of enzymes in the body (the enzyme plays a hydrogen transfer role in biological redox), and when the flavoenzymes are deficient, the biological oxidation of the body is influenced, so that metabolism is disturbed, and the pathological changes of the riboflavin are mostly expressed as inflammation of the mouth, eyes and external genitalia parts, such as angular stomatitis, cheilitis, glossitis, conjunctivitis, scrotitis and the like.
Compared with the prior art, the invention has the beneficial effects that:
the mouthwash spray for pets contains the traditional Chinese medicine components, the western medicine components and the buffer solution, can fully exert the synergistic effect between the traditional Chinese medicine components and the western medicine components, and has high effective medicine utilization degree, good effect and difficult generation of drug resistance when being used for preventing and treating oral diseases.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The invention provides a pet mouthwash spray, which comprises the following raw material components: traditional Chinese medicine components, western medicine components and pH buffer solution; according to the weight percentage, the weight percentage of the alloy is,
the traditional Chinese medicine composition accounts for 2.2-27%, and comprises the following components: 0.1-1% of tea polyphenol, 1-15% of chlorogenic acid, 0.1-1% of menthol and 1-10% of xylitol;
the western medicine components account for 1.3-14.5%, and include: 1-10% of ornidazole, 0.1-2% of lincomycin and 0.1-0.5% of mometasone furoateVitamin B2 0.1～2％；
The pH buffer solution accounts for 58.5-95.5%.
In the invention, western medicine components (ornidazole, lincomycin, mometasone furoate and vitamin B) are adopted by adopting traditional Chinese medicine components (tea polyphenol, chlorogenic acid, menthol and xylitol)2) The prepared mouthwash spray for pets can not only play the role of treatment regulation and deodorization of traditional Chinese medicines, but also play the broad-spectrum and powerful effects of antibiosis, anti-inflammation, antianaphylaxis, vasoconstriction, vascular permeability reduction, exudation reduction, cell division inhibition and the like of western medicines, the traditional Chinese medicines and the western medicines are mutually cooperated and enhance the curative effect in the aspects of protecting gum and eliminating halitosis, are mutually restricted in the aspect of immunosuppression of oral mucosa, can be used for local treatment of local diseases and reducing toxic and side effects, can be effectively used for treatment and prevention of oral diseases of pets, and are not easy to generate drug resistance. In the embodiment, preferably, the traditional Chinese medicine components account for 6-27%, the western medicine components account for 1.5-14%, and the pH buffer solution accounts for 61-87%. Further, the mass ratio of the traditional Chinese medicine components to the western medicine components is (0.4-4.5): 1. within the range, the synergistic effect between the traditional Chinese medicine components and the western medicine components can be more effectively exerted, and the obtained mouthwash has better curative effect. Further (0.4-2.5): 1.
in the invention, the chlorogenic acid and the menthol are compounded to be capable of enabling the chlorogenic acid and the menthol to act on cell membranes of aerobic bacteria in a synergistic manner, so that the normal pH value inside and outside the cells is changed, and the aim of killing the aerobic bacteria is fulfilled. In this embodiment, the mass ratio of chlorogenic acid to menthol is 1: (0.01-0.3). Within this ratio range, the synergistic effect of the two components can be more effectively exerted. Preferably 1: (0.02 to 0.03), more preferably 1: 0.03.
in the invention, the pH buffer solution is used for controlling the pH of the mouthwash spray for pets to be 6.5-7.5. The pH is too high or too low, so that certain stimulation is generated on enamel and gingiva; too high a pH may also promote calculus formation; the pH value is too low, so that the growth of normal flora such as streptococcus salivarius and the like in the oral cavity can be inhibited, the propagation of acid-producing bacteria and harmful bacteria is promoted, and the dental caries is aggravated. The specific type of the buffer solution is not particularly limited, and a person skilled in the art can select the corresponding type commonly used in the art to play a corresponding role. For example, the buffer selected may be a phosphate buffer and/or a carbonate buffer. In some specific embodiments of the invention, the pH buffer is a phosphate buffer, and the phosphate buffer consists of disodium hydrogen phosphate, sodium dihydrogen phosphate, and water. Further, in the phosphate buffer solution, the mass fraction of the disodium hydrogen phosphate is 0.454-1.945 wt%, and the mass fraction of the sodium dihydrogen phosphate is 0.756-2.016%. The pH value of the phosphate buffer solution at room temperature is 6.5-7.5.
The second aspect of the invention provides a preparation method of a mouthwash spray for pets, which comprises the following steps: the raw materials are proportioned according to the proportion and evenly mixed to obtain the solution type spray of the mouthwash for pets.
The preparation method of the pet mouthwash spray provided by the second aspect of the invention is used for obtaining the pet mouthwash spray provided by the first aspect of the invention.
For avoiding redundancy, in the following examples and comparative examples of the present invention, the composition of the phosphate buffer solution is: every 100g of phosphate buffer solution contains 0.454-1.945 g of disodium hydrogen phosphate, 0.756-2.016 g of sodium dihydrogen phosphate and 96.0836-98 g of water. The pH value of the phosphate buffer solution at room temperature is 6.5-7.5.
Example 1
The embodiment provides a mouthwash spray for pets, which comprises the following raw materials:
0.15g of tea polyphenol, 5g of chlorogenic acid, 0.15g of menthol, 2.5g of xylitol, 5g of ornidazole, 0.6g of lincomycin, 0.12g of mometasone furoate and vitamin B20.5g and 85.98g of phosphate buffer solution.
The embodiment also provides a preparation method of the mouthwash spray for pets, which comprises the following steps: the raw materials are proportioned according to the proportion, uniformly mixed and subpackaged into spray bottles to obtain the solution type spray of the mouthwash for pets.
Examples 2 to 7 and comparative examples 1 to 7 differ from example 1 only in that the raw material compositions are different, and the raw material compositions of examples 1 to 7 and comparative examples 1 to 7 are summarized in tables 1 and 2.
TABLE 1
TABLE 2
Test example 1
Animal experiments were conducted using the metronidazole solutions of examples 1 to 7, comparative examples 1 to 7 and 0.5% of the present invention.
3255 dogs with halitosis and stomatitis (blister, gingivitis and glossitis) in 12 small animal protection bases were randomly divided into 15 groups of 217 dogs. 15 groups of affected animals were treated with oral spray using the metronidazole solutions of examples 1-7, comparative examples 1-7 and 0.5% of the present invention, respectively. All dogs were treated once a day, morning and evening. The effect of treatment was observed after 14 days. The test results are shown in Table 3.
And (3) judging standard:
the disease is cured that the disease dog has normal eating and chewing actions, no pain (no salivation), no disappearance of ulcer surface, no fading of red swelling and no special odor (halitosis) in oral cavity;
is effective in improving or normalizing feeding and chewing action of dog, relieving or eliminating pain (less salivation), reducing or eliminating ulcer surface, relieving or eliminating red swelling, and reducing or eliminating special odor (halitosis) in oral cavity.
TABLE 3
As can be seen from table 3, the cure rate of the embodiments 1 to 7 of the present invention for treating oral diseases of pets is up to 93% or more, and the effective rate is up to 98% or more, which is obviously superior to that of the control group using only 0.5% metronidazole solution, indicating that the embodiments 1 to 7 of the present invention have good therapeutic effects for treating oral diseases of pets. Compared with example 1, the difference between example 6 and example 7 is only that the mass ratio of the chlorogenic acid to the menthol is different, which shows that the mass ratio of the chlorogenic acid to the menthol has an important influence on the quality effect of the oral diseases of the pets, and the higher or lower quality ratio is not beneficial to improving the treatment effect.
Compared with the embodiment 1, the curative rate and the effective rate of the oral diseases of the pets are poor due to the fact that less traditional Chinese medicine components and more western medicine components are added in the comparative example 1, and more traditional Chinese medicine components and less western medicine components are added in the comparative example 2, and it is proved that the contents of the traditional Chinese medicine components and the western medicine components in the formula need to be strictly controlled within a certain range, and the excessive components or the excessive components are not beneficial to fully exerting the synergistic effect of the traditional Chinese medicine components and the western medicine components.
Compared with the embodiment 1, in the comparative examples 3-7, ornidazole, tea polyphenol, lincomycin, mometasone furoate and chlorogenic acid are not added respectively, which shows that the synergistic effect of the components can be fully exerted only by limiting the content of the traditional Chinese medicine component and the western medicine component in the invention, so that the mouthwash spray with good treatment effect on the oral diseases of pets is obtained; the lack of any one component will result in its failure to act synergistically with the other components, which is detrimental to the improvement of therapeutic effect.
Compared with the prior art, the invention has the beneficial effects that:
the mouthwash spray for pets contains the traditional Chinese medicine components, the western medicine components and the buffer solution, can fully exert the synergistic effect between the traditional Chinese medicine components and the western medicine components, and has high effective medicine utilization degree, good effect and difficult generation of drug resistance when being used for preventing and treating oral diseases;
the mouthwash spray for pets can be used for treating and preventing oral diseases such as oral ulcer, gingivitis, periodontitis, glossitis, dental calculus, halitosis and the like of pets, and has the characteristics of oral deodorization, antibiosis, anti-inflammation, antianaphylaxis, local disease local treatment, low production cost, good curative effect, high safety and good economic benefit.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention.
Claims (7)
1. A pet mouthwash spray is characterized by comprising the following raw material components: traditional Chinese medicine components, western medicine components and pH buffer solution; according to the weight percentage, the weight percentage of the alloy is,
the traditional Chinese medicine component accounts for 2.2-27%, and consists of 0.1-1% of tea polyphenol, 1-15% of chlorogenic acid, 0.1-1% of menthol and 1-10% of xylitol; the mass ratio of the chlorogenic acid to the menthol is 1: (0.02-0.03);
the western medicine component accounts for 1.3-14.5%, and is composed of 1-10% of ornidazole, 0.1-2% of lincomycin, 0.1-0.5% of mometasone furoate, and vitamin B2 0.1-2%;
the pH buffer solution accounts for 58.5-95.5%.
2. The mouthwash spray for pets according to claim 1, wherein the traditional Chinese medicine components account for 6-27%, the western medicine components account for 1.5-14%, and the pH buffer accounts for 61-87%.
3. The mouthwash spray for pets according to claim 1, wherein the mass ratio of the traditional Chinese medicine components to the western medicine components is (0.4-4.5): 1.
4. the pet mouthwash spray according to claim 1, wherein the pH of the pet mouthwash spray is controlled to be 6.5-7.5.
5. The pet mouthwash spray according to claim 1, wherein the pH buffer is a phosphate buffer and/or a carbonate buffer.
6. The mouthwash spray for pets according to claim 5, wherein the phosphate buffer solution contains 0.454 to 1.945wt% of disodium hydrogen phosphate and 0.756 to 2.016wt% of sodium dihydrogen phosphate.
7. A method for preparing a pet mouthwash spray according to any one of claims 1 to 6, comprising the following steps: the raw materials are proportioned according to the proportion and evenly mixed to obtain the solution type spray of the mouthwash for pets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010965262.7A CN112121105B (en) | 2020-09-15 | 2020-09-15 | Mouthwash spray for pets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010965262.7A CN112121105B (en) | 2020-09-15 | 2020-09-15 | Mouthwash spray for pets and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112121105A CN112121105A (en) | 2020-12-25 |
| CN112121105B true CN112121105B (en) | 2022-04-26 |
Family
ID=73846776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010965262.7A Active CN112121105B (en) | 2020-09-15 | 2020-09-15 | Mouthwash spray for pets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112121105B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113750011A (en) * | 2021-10-09 | 2021-12-07 | 研维科技（上海）有限公司 | Pet tartar removing liquid and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108939079A (en) * | 2018-07-30 | 2018-12-07 | 郑州兰茜生物工程有限公司 | A kind of oral health agent of clearing heat and detoxicating antibacterial anti-inflammatory and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8858920B2 (en) * | 2004-12-21 | 2014-10-14 | Colgate-Palmolive Company | Anti-caries oral care composition with xylitol |
| CN101138586A (en) * | 2006-09-08 | 2008-03-12 | 王治效 | Riboflavin natural indigo mouth ulcer paster |
| US10392371B2 (en) * | 2015-10-01 | 2019-08-27 | Senomyx, Inc. | Compounds useful as modulators of TRPM8 |
| CN106938046A (en) * | 2017-03-16 | 2017-07-11 | 韦毅 | A kind of antibacterial peptide complex enzyme oral spray |
| CN108992663A (en) * | 2018-09-04 | 2018-12-14 | 山东亚华生物科技有限公司 | It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease |
| CN110339175A (en) * | 2019-08-19 | 2019-10-18 | 云南农业大学 | A kind of tea polyphenol buccal tablet preventing and treating canker sore |
| CN111358851A (en) * | 2020-04-13 | 2020-07-03 | 长江大学 | Gel for treating pet skin diseases and preparation method thereof |
-
2020
- 2020-09-15 CN CN202010965262.7A patent/CN112121105B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108939079A (en) * | 2018-07-30 | 2018-12-07 | 郑州兰茜生物工程有限公司 | A kind of oral health agent of clearing heat and detoxicating antibacterial anti-inflammatory and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112121105A (en) | 2020-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110151594B (en) | Oral composition containing ectoin and hyaluronic acid and application thereof | |
| EP1959988B2 (en) | Use of bovine lactoferrin for treating destructive inflammation of mucous membrane | |
| NO331654B1 (en) | Xylitol mixtures, pharmaceutical preparations, nasal sprays and medicated swab. | |
| US11801275B2 (en) | Compositions and methods for common colds | |
| JP2017529400A (en) | Mangosteen extract or composition for preventing or ameliorating periodontal disease comprising alpha and gamma mangosteen as active ingredients | |
| US20100234317A1 (en) | Use of difructose anhydride-containing composition | |
| WO2018062605A1 (en) | Toothpaste composition containing galenical extract | |
| KR20190000955A (en) | Composition for preventing or treating periodontal disease comprising extracts of herbal mixture | |
| WO2019088412A1 (en) | Composition containing tea extract with increased specific ingredient content for prevention or alleviation of lipid metabolism disorders | |
| CN112121105B (en) | Mouthwash spray for pets and preparation method thereof | |
| JP5754711B2 (en) | Oral hygiene composition effective in promoting salivation and oral care product | |
| KR20170141053A (en) | Composition for prevention or treatment of dental disease comprising an extract of Gardenia jasminoides | |
| KR20130123861A (en) | Composition for cleaning oral cavity containing fucoidan | |
| US20060135498A1 (en) | Compositions useful for the treatment of microbial infections | |
| CN104324062A (en) | American ginseng conversion saponin, traditional Chinese medicine mouth care composition thereof and preparation method and application | |
| CN112755179A (en) | Composition for preventing and treating helicobacter pylori in oral cavity and application thereof | |
| KR20170141027A (en) | Composition for prevention or treatment of dental disease comprising an extract of Astragalus membranaceus | |
| KR101078765B1 (en) | Edible composition for prevention of periodontal disease by growth of bacteria in the mouth | |
| CN110787288A (en) | Medical collagen oral ulcer protective gel and preparation method thereof | |
| KR100474534B1 (en) | Pharmaceutical Composition for Prophylaxis and Treatment of Dental Diseases | |
| RU2813879C1 (en) | Anti-inflammatory composition (versions) for local application in oral cavity and upper respiratory tract | |
| EP2535047A1 (en) | Nutritional composition, food supplement comprising said nutritional composition and kit comprising said food supplement | |
| KR102097387B1 (en) | A composition for preventing and treating oral disease comprising black rice | |
| CN109568428B (en) | Yongquan plaster for children | |
| KR20230151286A (en) | Composition for preventing or treating periodontal disease comprising ginsenoside compound K or complex ginsenoside composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |